{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:53:13Z","timestamp":1782247993645,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1476-4598-13-227","type":"journal-article","created":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T09:05:58Z","timestamp":1412240758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Agonist activation of estrogen receptor beta (ER\u03b2) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity"],"prefix":"10.1186","volume":"13","author":[{"given":"Giulia","family":"Pinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangela G","family":"Manente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Daga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"issue":"4","key":"1428_CR1","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM: Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012, 1 (4): 491-496.","journal-title":"Ann Cardiothorac Surg"},{"issue":"1","key":"1428_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/crj.12028","volume":"8","author":"S Prazakova","year":"2013","unstructured":"Prazakova S, Thomas PS, Sandrini A, Yates DH: Asbestos and the lung in the 21st century: an update. Clin Respir J. 2013, 8 (1): 1-10.","journal-title":"Clin Respir J"},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","volume":"34","author":"L Stayner","year":"2013","unstructured":"Stayner L, Welch LS, Lemen R: The worldwide pandemic of asbests-related diseases. Annu Rev Public Health. 2013, 34: 205-216. 10.1146\/annurev-publhealth-031811-124704","journal-title":"Annu Rev Public Health"},{"issue":"15","key":"1428_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.addr.2013.07.014","volume":"65","author":"K Donaldson","year":"2013","unstructured":"Donaldson K, Poland CA, Murphy FA, Macfarlane M, Chernova T, Schinwald A: Pulmonary toxicity of carbon nanotubes and asbestos - Similarities and differences. Adv Drug Deliv Rev. 2013, 65 (15): 2078-2086. 10.1016\/j.addr.2013.07.014","journal-title":"Adv Drug Deliv Rev"},{"issue":"15","key":"1428_CR5","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/j.addr.2013.09.005","volume":"65","author":"H Dumortier","year":"2013","unstructured":"Dumortier H: When carbon nanotubes encounter the immune system: desirable and undesirable effects. Adv Drug Deliv Rev. 2013, 65 (15): 2120-2126. 10.1016\/j.addr.2013.09.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"15","key":"1428_CR6","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.addr.2013.05.012","volume":"65","author":"K Bhattacharya","year":"2013","unstructured":"Bhattacharya K, And\u00f3n FT, El-Sayed R, Fadeel B: Mechanisms of carbon nanotube-induced toxicity: focus on pulmonary inflammation. Adv Drug Deliv Rev. 2013, 65 (15): 2087-2097. 10.1016\/j.addr.2013.05.012","journal-title":"Adv Drug Deliv Rev"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1055\/s-0031-1272874","volume":"32","author":"NP Campbell","year":"2011","unstructured":"Campbell NP, Kindler HL: Update on malignant pleural mesothelioma. Semin Respir Crit Care Med. 2011, 32: 102-110. Review","journal-title":"Semin Respir Crit Care Med"},{"issue":"4","key":"1428_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","volume":"182","author":"BT Mossman","year":"2013","unstructured":"Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R: New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol. 2013, 182 (4): 1065-1077. 10.1016\/j.ajpath.2012.12.028","journal-title":"Am J Pathol"},{"key":"1428_CR9","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in cobination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 21: 2636-2644. 10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"issue":"3","key":"1428_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin C, Hillerdal G, Le P\u00e9choux C, Mutti L, Pairon JC, Stahel R, van Houtte P, van Meerbeeck J, Waller D, Weder W: Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Society\/European Society of Thoracic Surgeons Task Force. Eur Respir J. 2010, 35 (3): 479-495. 10.1183\/09031936.00063109","journal-title":"Eur Respir J"},{"issue":"1","key":"1428_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ccm.2012.12.005","volume":"34","author":"AR Haas","year":"2013","unstructured":"Haas AR, Sterman DH: Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med. 2013, 34 (1): 99-111. 10.1016\/j.ccm.2012.12.005","journal-title":"Clin Chest Med"},{"issue":"10","key":"1428_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/13543784.2013.816281","volume":"22","author":"G Pinton","year":"2013","unstructured":"Pinton G, Manente AG, Tavian D, Moro L, Mutti L: Therapies currently in Phase II trials for malignant pleural mesothelioma. Expert Opin Investig Drugs. 2013, 22 (10): 1255-1263. 10.1517\/13543784.2013.816281","journal-title":"Expert Opin Investig Drugs"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-08-4523","volume":"69","author":"G Pinton","year":"2009","unstructured":"Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69: 4598-4604. 10.1158\/0008-5472.CAN-08-4523","journal-title":"Cancer Res"},{"issue":"6","key":"1428_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00432-013-1408-2","volume":"139","author":"K Pillai","year":"2013","unstructured":"Pillai K, Pourgholami MH, Chua TC, Morris DL: Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 2013, 139 (6): 987-994. 10.1007\/s00432-013-1408-2","journal-title":"J Cancer Res Clin Oncol"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"e14110","DOI":"10.1371\/journal.pone.0014110","volume":"5","author":"G Pinton","year":"2010","unstructured":"Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, Mutti L, Moro L: Estrogen receptor \u03b2 exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS ONE. 2010, 5: e14110- 10.1371\/journal.pone.0014110","journal-title":"PLoS ONE"},{"key":"1428_CR16","first-page":"4258","volume":"82","author":"E Enmark","year":"1997","unstructured":"Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskj\u00f6ld M, Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab. 1997, 82: 4258-4265.","journal-title":"J Clin Endocrinol Metab"},{"key":"1428_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mce.2007.11.020","volume":"283","author":"JE Mersereau","year":"2008","unstructured":"Mersereau JE, Levy N, Staub RE, Baggett S, Zogovic T, Chow S, Ricke WA, Tagliaferri M, Cohen I, Bjeldanes LF, Leitman DC: Liquiritigenin is a plant-derived highly selective estrogen receptor \u03b2 agonist. Mol Cell Endocrinol. 2008, 283: 49-57. 10.1016\/j.mce.2007.11.020","journal-title":"Mol Cell Endocrinol"},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.1158\/0008-5472.CAN-06-0017","volume":"66","author":"J Hartman","year":"2006","unstructured":"Hartman J, Lindberg K, Morani A, Inzunza J, Str\u00f6m A, Gustafsson JA: Estrogen receptor \u03b2 inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res. 2006, 66: 11207-11213. 10.1158\/0008-5472.CAN-06-0017","journal-title":"Cancer Res"},{"key":"1428_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nrd3551","volume":"10","author":"S Nilsson","year":"2011","unstructured":"Nilsson S, Koehler KF, Gustafsson J\u00c5: Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov. 2011, 10: 778-792. Review, 10.1038\/nrd3551","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"1428_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrc3093","volume":"11","author":"C Thomas","year":"2011","unstructured":"Thomas C, Gustafsson J\u00c5: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011, 11 (8): 597-608. 10.1038\/nrc3093","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1428_CR21","doi-asserted-by":"publisher","first-page":"T61","DOI":"10.1530\/JME-13-0150","volume":"51","author":"P Dey","year":"2013","unstructured":"Dey P, Barros RP, Warner M, Strom A, Gustafsson J\u00c5: Insight into the mechanisms of action of estrogen receptor beta. J Mol Endocrinol. 2013, 51 (3): T61-T74. 10.1530\/JME-13-0150","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"1428_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0031-1299592","volume":"30","author":"LC Murphy","year":"2012","unstructured":"Murphy LC, Leygue E: The role of estrogen receptor-\u03b2 in breast cancer. Semin Reprod Med. 2012, 30 (1): 5-13. Review","journal-title":"Semin Reprod Med"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/bjc.2012.323","volume":"107","author":"A Rudolph","year":"2012","unstructured":"Rudolph A, Toth C, Hoffmeister M, Roth W, Herpel E, Jansen L, Marx A, Brenner H, Chang-Claude J: Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br J Cancer. 2012, 107: 831-839. 10.1038\/bjc.2012.323","journal-title":"Br J Cancer"},{"issue":"19","key":"1428_CR24","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.2174\/138161212800626139","volume":"18","author":"D Gallo","year":"2012","unstructured":"Gallo D, De Stefano I, Prisco MG, Scambia G, Ferrandina G: Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des. 2012, 18 (19): 2734-2757. 10.2174\/138161212800626139","journal-title":"Curr Pharm Des"},{"key":"1428_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mce.2013.05.016","volume":"375","author":"K Yakimchuck","year":"2013","unstructured":"Yakimchuck K, Jondal M, Okret S: Estrogen receptor alpha and beta in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol. 2013, 375: 121-129. 10.1016\/j.mce.2013.05.016","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"1428_CR26","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mdt132","volume":"24","author":"Y Yan","year":"2013","unstructured":"Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC: Expression of both Estrogen Receptor-beta 1 (ER-\u03b21) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-\u03b1)-Negative Early Breast Cancer (EBC). Ann Oncol. 2013, 24 (8): 1986-1993. 10.1093\/annonc\/mdt132","journal-title":"Ann Oncol"},{"key":"1428_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1752-1947-5-36","volume":"5","author":"K Pillai","year":"2011","unstructured":"Pillai K, Akhter J, Pourgholami MH, Morris DL: Peritoneal mesothelioma in a woman who has survived for seven years: a case report. J Med Case Rep. 2011, 5: 36- 10.1186\/1752-1947-5-36","journal-title":"J Med Case Rep"},{"issue":"21","key":"1428_CR28","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1158\/1078-0432.CCR-13-0325","volume":"19","author":"A Barzi","year":"2013","unstructured":"Barzi A, Lenz A, Labonte MJ, Lenz HJ: Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res. 2013, 19 (21): 5842-5848. 10.1158\/1078-0432.CCR-13-0325","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"1428_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsbmb.2011.12.018","volume":"130","author":"X Song","year":"2012","unstructured":"Song X, Pan ZZ: Estrogen receptor-beta agonist diarylpropionitrile counteracts the estrogenic activity of estrogen receptor-alpha agonist propylpyrazole-triol in the mammary gland of ovariectomized Sprague Dawley rats. J Steroid Biochem Mol Biol. 2012, 130 (1\u20132): 26-35.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1428_CR30","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1210\/en.2002-0143","volume":"144","author":"J Frasor","year":"2003","unstructured":"Frasor J, Barnett DH, Danes JM, Hess R, Parlow AF, Katzenellenbogen BS: Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) \u03b1 activity by ER\u03b2 in the uterus. Endocrinology. 2003, 144: 3159-3166. 10.1210\/en.2002-0143","journal-title":"Endocrinology"},{"key":"1428_CR31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","volume":"369","author":"V Beral","year":"2007","unstructured":"Beral V, Bull D, Green J, Reeves G: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007, 369: 1703-1710.","journal-title":"Lancet"},{"key":"1428_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrc2174","volume":"7","author":"SJ Ellem","year":"2007","unstructured":"Ellem SJ, Risbridger GP: Treating prostate cancer: a rationale for targeting local oestrogens. Nat Rev Cancer. 2007, 7: 621-627. Review, 10.1038\/nrc2174","journal-title":"Nat Rev Cancer"},{"key":"1428_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1210\/me.2004-0050","volume":"18","author":"A Hillish","year":"2004","unstructured":"Hillish A, Peters O, Kosemund D, M\u00fcller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH: Dissecting physiological roles of estrogen receptor \u03b1 and \u03b2 with potent selective ligands. Mol Endocrinol. 2004, 18: 1599-1609. 10.1210\/me.2004-0050","journal-title":"Mol Endocrinol"},{"key":"1428_CR34","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/jm201436k","volume":"55","author":"VM Carroll","year":"2012","unstructured":"Carroll VM, Jeyakumar M, Carlson KE, Katzenellenbogen JA: Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor \u03b2-selective ligands. J Med Chem. 2012, 55: 528-537. 10.1021\/jm201436k","journal-title":"J Med Chem"},{"key":"1428_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/med.20186","volume":"31","author":"F Minutolo","year":"2011","unstructured":"Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA: Estrogen receptor \u03b2 ligands: recent advances and biomedical applications. Med Res Rev. 2011, 31: 364-442. 10.1002\/med.20186","journal-title":"Med Res Rev"},{"key":"1428_CR36","volume-title":"Steroids","author":"I Paterni","year":"2014","unstructured":"Paterni I, Granchi C, Katzenellenbogen JA, Minutolo F: Estrogen receptor alpha (ER\u03b1) and beta (ER\u03b2): Subtype-selective ligands and clinical potential. Steroids. 2014, Epub ahead of print"},{"key":"1428_CR37","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/pros.21507","volume":"72","author":"DM Attia","year":"2012","unstructured":"Attia DM, Ederveen AG: Opposing roles of ER\u03b1 and ER\u03b2 in the genesis and progression of adenocarcinoma in the rat ventral prostate. Prostate. 2012, 72: 1013-1022. 10.1002\/pros.21507","journal-title":"Prostate"},{"key":"1428_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mc.20719","volume":"50","author":"V Giroux","year":"2011","unstructured":"Giroux V, Bernatchez G, Carrier JC: Chemopreventive Effect of ER\u03b2-selective agonist on intestinal tumorigenesis in ApcMin\/+ Mice. Mol Carcinog. 2011, 50: 359-369. 10.1002\/mc.20719","journal-title":"Mol Carcinog"},{"key":"1428_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.canlet.2011.05.004","volume":"308","author":"M Mancuso","year":"2011","unstructured":"Mancuso M, Leonardi S, Giardullo P, Pasquali E, Borra F, Stefano ID, Prisco MG, Tanori M, Scambia G, Majo VD, Pazzaglia S, Saran A, Gallo D: The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways. Cancer Lett. 2011, 308: 197-202. 10.1016\/j.canlet.2011.05.004","journal-title":"Cancer Lett"},{"issue":"5","key":"1428_CR40","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/1535-7163.MCT-11-0960","volume":"11","author":"GR Sareddy","year":"2012","unstructured":"Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK: Therapeutic significance of estrogen receptor \u03b2 agonists in gliomas. Mol Cancer Ther. 2012, 11 (5): 1174-1182. 10.1158\/1535-7163.MCT-11-0960","journal-title":"Mol Cancer Ther"},{"key":"1428_CR41","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/leu.2011.68","volume":"25","author":"K Yakimchuk","year":"2011","unstructured":"Yakimchuk K, Iravani M, Hasni MS, Rh\u00f6nnstad P, Nilsson S, Jondal M, Okret S: Effect of ligand-activated estrogen receptor \u03b2 on lymphoma growth in vitro and in vivo. Leukemia. 2011, 25: 1103-1110.","journal-title":"Leukemia"},{"key":"1428_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.dld.2011.06.014","volume":"44","author":"M Marzioni","year":"2012","unstructured":"Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantelli I, Rh\u00f6nnstad P, Trozzi L, Apelqvist T, Gentile R, Candelaresi C, Fava G, Semeraro R, Benedetti A, Gaudio E, Franchitto A, Onori P, De Minicis S, Carpino G, Kallin E, Alvaro D, Nilsson S: An oestrogen receptor \u03b2-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Dig Liver Dis. 2012, 44: 134-142. 10.1016\/j.dld.2011.06.014","journal-title":"Dig Liver Dis"},{"key":"1428_CR43","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1038\/oncsis.2013.32","volume":"2","author":"AG Manente","year":"2013","unstructured":"Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O\u2019Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L: Estrogen receptor \u03b2 activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis. 2013, 2: e72- 10.1038\/oncsis.2013.32","journal-title":"Oncogenesis"},{"key":"1428_CR44","doi-asserted-by":"publisher","first-page":"e36856","DOI":"10.1371\/journal.pone.0036856","volume":"7","author":"G Pinton","year":"2012","unstructured":"Pinton G, Manente AG, Angeli G, Mutti L, Moro L: Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE. 2012, 7: e36856- 10.1371\/journal.pone.0036856","journal-title":"PLoS ONE"},{"key":"1428_CR45","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","volume":"39","author":"J Remon","year":"2013","unstructured":"Remon J, Lianes P, Mart\u00ednez S, Velasco M, Querol R, Zanui M: Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev. 2013, 39: 584-591. 10.1016\/j.ctrv.2012.12.005","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1428_CR46","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/10408440591034502","volume":"35","author":"EJ Calabrese","year":"2005","unstructured":"Calabrese EJ: Cancer biology and hormesis; human tumor cell lines commonly display hormetic (biphasic) dose response. Crit Rev Toxicol. 2005, 35 (6): 463-582. 10.1080\/10408440591034502","journal-title":"Crit Rev Toxicol"},{"key":"1428_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.envpol.2013.07.046","volume":"182","author":"EJ Calabrese","year":"2013","unstructured":"Calabrese EJ: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features. Environ Pollut. 2013, 182: 452-460.","journal-title":"Environ Pollut"},{"issue":"5","key":"1428_CR48","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00018-002-8470-2","volume":"59","author":"G Reid","year":"2002","unstructured":"Reid G, Denger S, Kos M, Gannon F: Human estrogen receptor-alpha: regulation by synthesis, modification and degradation. Cell Mol Life Sci. 2002, 59 (5): 821-831. 10.1007\/s00018-002-8470-2","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1428_CR49","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1097-2765(03)00090-X","volume":"11","author":"G Reid","year":"2003","unstructured":"Reid G, H\u00fcbner MR, M\u00e9tivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F: Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell. 2003, 11 (3): 695-707. 10.1016\/S1097-2765(03)00090-X","journal-title":"Mol Cell"},{"key":"1428_CR50","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","volume":"24","author":"DA Altomare","year":"2005","unstructured":"Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR: Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005, 24: 6080-6089. 10.1038\/sj.onc.1208744","journal-title":"Oncogene"},{"key":"1428_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00280-007-0500-1","volume":"61","author":"GJ Gordon","year":"2008","unstructured":"Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R: Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2008, 61: 549-558. 10.1007\/s00280-007-0500-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"1428_CR52","doi-asserted-by":"publisher","first-page":"8910","DOI":"10.1158\/0008-5472.CAN-09-1543","volume":"69","author":"e-SA Arafa","year":"2009","unstructured":"Arafa e-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase\/Akt signaling pathway. Cancer Res. 2009, 69: 8910-8917. 10.1158\/0008-5472.CAN-09-1543","journal-title":"Cancer Res"},{"key":"1428_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/35035131","volume":"407","author":"T Simoncini","year":"2000","unstructured":"Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000, 407: 538-541. 10.1038\/35035131","journal-title":"Nature"},{"issue":"37","key":"1428_CR54","doi-asserted-by":"publisher","first-page":"9439","DOI":"10.1523\/JNEUROSCI.1443-06.2006","volume":"26","author":"P Mannella","year":"2006","unstructured":"Mannella P, Brinton RD: Estrogen receptor protein interaction with phosphatidylinositol 3- kinase leads to activation of phosphorylated Akt and extracellular signal-regulated kinase 1\/2 in the same population of cortical neurons: a unified mechanism of estrogen action. J Neurosci. 2006, 26 (37): 9439-9447. 10.1523\/JNEUROSCI.1443-06.2006","journal-title":"J Neurosci"},{"key":"1428_CR55","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.1073\/pnas.211026798","volume":"98","author":"P Cacciotti","year":"2001","unstructured":"Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, Gaudino G: SV40 replication in human mesothelial cells induces HGF\/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci U S A. 2001, 98: 12032-12037. 10.1073\/pnas.211026798","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1428_CR56","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0003-4975(95)00045-M","volume":"59","author":"HI Pass","year":"1995","unstructured":"Pass HI, Stevens EJ, Oie H, Tsokos MG, Abati AD, Fetsch PA, Mew DJ, Pogrebniak HW, Matthews WJ: Characteristics of nine newly derived mesothelioma cell lines. Ann Thorac Surg. 1995, 59 (4): 835-844. 10.1016\/0003-4975(95)00045-M","journal-title":"Ann Thorac Surg"},{"key":"1428_CR57","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2012","unstructured":"R Core Team, : R: A Language and Environment for Statistical Computing. 2012, ISBN 3-900051-07-0, URL http:\/\/www.R-project.org\/, Vienna, Austria: R Foundation for Statistical Computing"},{"issue":"1","key":"1428_CR58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.54.1.105","volume":"54","author":"T Barkhem","year":"1998","unstructured":"Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S: Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists\/antagonists. Mol Pharmacol. 1998, 54 (1): 105-112.","journal-title":"Mol Pharmacol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-4598-13-227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T06:02:19Z","timestamp":1630562539000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/1476-4598-13-227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1186\/1476-4598-13-227","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,2]]},"assertion":[{"value":"15 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"227"}}